



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
13/06/2017 10.15 - 11.55 Antiretroviral Therapy			
<i>Aula 1 Chairs: P. Bonfanti, A.M. Cattelan, G. Carosi</i>			
		Minilecture: Pharmacoeconomic models including generic ARV drugs for cost containment	<i>Umberto Restelli, Castellanza VA</i>
211	OC 1	Early start of antiretroviral therapy during Primary HIV Infection is associated with faster optimal immunological recovery – Final results of Italian Network of ACuTe HIV InfectiON (INACTiON) retrospective study	<i>Antonio Muscatello, Monza</i>
379	OC 2	Virological control in patients early switching versus maintaining initial antiretroviral therapy (ART) during primary HIV-1 infection (PHI): experience from an Italian cohort	<i>Annalisa Mondì, Roma</i>
381	OC 3	2-years efficacy and durability of simplification to Single Tablet Regimen (STR): a comparison between co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir	<i>Roberta Gagliardini, Roma</i>
397	OC 4	A preliminary pharmacoeconomics analysis of the impact of ABC/3TC/DTG and TDF/FTC/EVG/cobi in HIV +, virologically suppressed patients	<i>Umberto Restelli, Castellanza (VA)</i>
112	OC 5	Time spent with residual viremia after virological suppression according to type of first-line antiretroviral regimen	<i>Nicola Gianotti, Milano</i>
193	OC 6	Factors related to over-time viral failure in HIV-infected patients with previous C-ART failures	<i>Stefano Rusconi, Milano</i>
375	OC 7	48-week results of a dual therapy with Darunavir/rtv plus Rilpivirine QD vs triple therapy in patients with suppressed viraemia: virological efficacy and non-HIV related morbidity evaluation	<i>Valentina Di Cristo, Milano</i>
179	OC 8	Efficacy and discontinuation of dual regimens with 3TC plus PI/r in patients from clinical practice enrolled in ARCA	<i>Domenico Di Carlo, Roma</i>
13/06/2017 10.15 - 11.55 Immunology			
<i>Aula 2 Chairs: A. De Maria, L. Lopalco, G. Marchetti</i>			
		Minilecture: "The interferon activity in viral infections: a double edged sword"	<i>Guido Antonelli, Roma</i>
294	OC 9	Innate immune remodelling in advanced and non-advanced HIV presenters after two years of effective antiretroviral therapy	<i>Stefano Savinelli, Roma</i>
116	OC 10	Toll like receptors, type I/III interferon and retroviral restriction factors in HIV-1 infected patients: expression in gut mucosa and in peripheral blood mononuclear cells and their modification upon probiotics supplementation	<i>Claudia Pinacchio, Roma</i>
70	OC 11	The expression of host restriction factors was affected by ageing and was not associated to residual viremia in HIV-1 infected patients on long-term antiretroviral therapy	<i>Maura Statzu, Roma</i>
123	OC 12	Dynamic modulation of immune activation in the peripheral blood and in the GUT of HIV infected patients after probiotic supplementation	<i>Ivan Schietroma, Roma</i>
54	OC 13	Immunological non-response in HIV-infected patients under effective ART is associated with increased circulating Th17 T helper cells	<i>Ilaria De Benedetto, Monza</i>
178	OC 14	Role of phosphorylation in the CCR5 signalosome formation by antibodies to CCR5 in HIV-infected Long Term Non Progressors subjects	<i>Gabriel Siracusano, Milano</i>
333	OC 15	Dynamics of CD4/CD8 ratio evolution and predictors of its normalization after initiation of antiretroviral therapy in naïve HIV-infected patients	<i>Massimiliano Fabbiani, Monza</i>
382	OC 16	HBV vaccination in HIV-infected people: immunogenicity and immunomodulatory role of vitamin D	<i>Laura Ambra Nicolini, Genova</i>
13/06/2017 14.50 - 16.05 Immunological response under cART and co-infections			
<i>Aula 1 Chairs: O. Armignacco, F. Menichetti, F. Maggiolo</i>			
		Minilecture: Is search and treat for latent TB still valid in the undetectability era?	<i>Enrico Girardi, Roma</i>
286	OC 17	CD4/CD8 ratio in patients who switch therapy: better triple therapy than dual/mono?	<i>Cristina Mussini, Modena</i>
329	OC 18	CD4/CD8 ratio matters to age related health outcomes in HIV infected patients with comorbidities, frailty and disability	<i>Marianna Menozzi, Modena</i>
404	OC 19	Value of CD4 count nadir and of time since occurrence of CD4 count nadir to predict viral rebound in a selected population who underwent a therapy switch after achieving viral suppression	<i>Mauro Zaccarelli, Roma</i>
259	OC 20	Altered intestinal microbiota in successfully cART-treated HIV-infected males with high-risk HPV genotypes and anal HPV-related cytological abnormalities	<i>Esther Merlini, Milano</i>
177	OC 21	Predictive factors for HPV infection and neoplastic cervical lesions among 321 HIV+ women at Santa Maria Annunziata Hospital, Florence, 2006-2016	<i>Francesco Maria Fusco, Bagno a Ripoli (FI)</i>
344	OC 22	Multi-site HPV infection in HIV-positive men	<i>Alessandra Vergori, Roma</i>
13/06/2017 14.50 - 16.05 Clinical Hepatitis I			
<i>Aula 2 Chiars: C. Ferrari, F. Mazzotta, M. Tavio</i>			
49	OC 23	Treatment with DAAs in a multicenter cohort of HCV-infected prisoners in Italy	<i>Emanuele Pontali, Genova</i>
29	OC 24	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens: a prospective study	<i>Lucio Boglione, Torino</i>
319	OC 25	Successful DAA treatment of HCV in a complete clinical series with advanced fibrosis, including a high success rate of re-treatment using HCV resistance guidance	<i>Barbara Rossetti, Siena</i>



Elenco Oral Communication Oral Communications

ID	N. pgm	Title	Presenting Author
335	OC 26	Sustained virological response in HIV/HCV co-infected patients: long term impact on liver disease progression and renal performance	Diletta Barbanotti, Milano
130	OC 27	Renal function changes in HCV-infected patients with CKD during and after treatment with direct antiviral agents (DAAs)	Raffaele Dell'Acqua, Bari
384	OC 28	Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in HCV Child-A cirrhosis	Donatella Palazzo, Roma
411	OC 29	Evolution of eGFR and proteinuria in HCV+ patients treated with DAA regimen containing ledipasvir with or without tenofovir disoproxil fumarate	Roberta Gagliardini, Roma
13/06/2017 16.20 - 18.00 Complication of cART			
<i>Aula 1 Chairs: R. Cauda, C. Gervasoni, R. Maserati</i>			
		Minilecture: Frailty in aging with HIV infection	Giovanni Guaraldi, Modena
133	OC 30	Risk of low anti-Mullerian Hormone (AMH) in HIV-positive women on virologically-suppressive antiretroviral therapy	Esther Merlini, Milano
367	OC 31	Prevalence and predictors of early menopause in a cohort of HIV-infected climacteric women: comparison with sero-negative patients and effects on BMD	Alessandro D'Avino, Roma
199	OC 32	Cardiovascular adverse events during treatment with darunavir-based regimens in an italian observational study	Stefano Rusconi, Milano
166	OC 33	Clinical impact of HIV-1 coreceptor tropism: a syllogistic linkage with old (CD4/CD8 ratio) and new (VACS Index) tools	Armando Leone, Bari
265	OC 34	Switching to dolutegravir-based regimens is beneficial in HIV positive patients experienced to cART	Paola Nasta, Brescia
219	OC 35	Lipid profile changed after switch to Dolutegravir+3TC/ABC in HIV-infected patients with undetectable HIV-RNA: results from the SCOLTA cohort	Paola Bagella, Sassari
334	OC 36	Efficacy and discontinuation rates of tenofovir/emtricitabine/elvitegravir/cobicistat in routine clinical practice: data from a multicenter cohort	Massimiliano Fabbiani, Monza
208	OC 37	Effects of cobicistat on tenofovir tolerability: is it time to rethink at TAF trials?	Andrea Giacomelli, Milano
13/06/2017 16.20 - 18.00 HIV & HCV: From education to care			
<i>Aula 2 Chairs: M.G. Di Benedetto, M. Errico, M. Stagnitta</i>			
31	OC 38	Educational and training initiatives increase participants' awareness about HIV	Laura A. Rancilio, Milano
331	OC 39	Sexual health (SH), adherence to antiretroviral therapy, and virologic suppression: a descriptive study in HIV sero-discordant couples (Passion Study)	Carmela Pinnetti, Roma
152	OC 40	A project of health education in schools: knowledge on HIV/AIDS of a sample of teenagers in Rome	Massimo Farinella, Roma
227	OC 41	Facilitators of treatment adherence with direct acting antivirals in HCV genotype 3 infected people who inject drugs: the key to success?	Emanuela Ciraci, Ostuni BR
190	OC 42	Fear for HIV-stigma as a driver for invisibility within the MSM community in Italy: results from a national survey	Giulio Maria Corbelli, Roma
188	OC 43	Epidemiological evaluation of people tested for HIV in Perugia in 2015-2016: what can be done better?	Carlo Pallotto, Perugia
19	OC 44	Predictors of retention in care in HIV-infected patients: data from San Martino hospital cohort in Genoa	Roberta Prinapori, La Spezia
35	OC 45	HIV positive people not-retained in care in Piedmont: an evaluation of data from the regional surveillance	Laura Camoni, Roma
184	OC 46	Villa Maraini Foundation's HIV/HCV Continuum of Care Model Among Hard to Reach Drug Addicts and Sex Workers in Rome: the Need for Targeted Interventions	Elisabetta Teti, Roma
14/06/2017 09.05 - 10.30 Clinical Hepatitis II			
<i>Aula 1 Chairs: G. D'Offizi, G. Rizzardini, C. Torti</i>			
		Minilecture: "Cost-effectiveness of eradication models in HCV and HIV-HCV	Yazdan Yazdanpanah, Paris
117	OC 47	Specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlate with high viremia and hamper HBsAg detection and quantification	Lorenzo Piermatteo, Roma
40	OC 48	Extended duration of treatment with pegylated interferon alfa-2a in patients with active chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis	Lucio Boglione, Torino
119	OC 49	The degree of genetic variability in HBsAg C-terminus profoundly influence HBsAg levels in HBeAg-negative chronic HBV genotype D infection	Arianna Battisti, Roma
137	OC 50	Peripheral and intrahepatic virological characterization in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the "grey-zone" viral load cohort	Luna Colagrossi, Roma
225	OC 51	Clinical usefulness of accurate HCV genotype and subtype assignment by HCV sequencing in more genomic regions in the era of new direct acting antiviral agents	Marianna Aragri, Roma
383	OC 52	Meaning and correlates of detectable HCV residual viremia in HIV/HCV coinfecting and HCV monoinfected patients	Ilaria Mastroianni, Roma
226	OC 53	NS5A-resistance may reduce NS5A-based retreatment efficacy after DAA-failure: a real-life experience	Valeria Cento, Roma



Elenco Oral Communication Oral Communications

ID	N. pgm	Title	Presenting Author
14/06/2017 09.05 - 10.30 HIV Epidemiology and Prevention			
<i>Aula 2 Chairs: S. Babudieri, G. Ippolito, G. Rezza</i>			
210	OC 54	Dynamics of HIV-1 Transmission Clusters In Newly Diagnosed Individuals Between 2004-2016 In Italy	Lavinia Fabeni, Roma
312	OC 55	Evolution of transmitted HIV-1 drug resistance in Italy from 2006 to 2016	Barbara Rossetti, Siena
95	OC 56	A multi-dimensional evaluation of PrEP adoption: the Italian perspective	Lucrezia Ferrario, Castellanza VA
42	OC 57	Pre-exposure prophylaxis knowledge and attitudes among sexually active men who have sex with men in Italy – Italian results of "Flash! PrEP in Europe", a European community-based study	Maria Luisa Cosmaro, Milano
322	OC 58	"Let's do it Fast": an outreach program of HIV rapid testing for general population in Rome by Anlaidis Lazio and INMI Spallanzani	Nicoletta Orchi, Roma
386	OC 59	Adverse effects and associated treatment discontinuation of antiretroviral regimens used in HIV Post-Exposure Prophylaxis	Gabriella De Carli, Roma
387	OC 60	Gender differences in HCV exposure, active replication and genotypes in HIV patients entering care in Italy	Barbara Rossetti, Siena
101	OC 61	HCV and HCV/HIV coinfecting patients known to Tuscan Regional Health Service in 2016	Cristina Stasi, Firenze
14/06/2017 10.35 - 11.55 Comorbidities			
<i>Aula 1 Chairs: L. Calza, P. Cinque, C.M. Mastroianni</i>			
		Minilecture: CSF biomarkers for research and clinical purpose in HIV	Magnum Gisslén, Göteborg
414	OC 62	24 months follow-up of PROJECT STOP Smoking in HIV patients (STOPS HIV)	Giuseppe De Socio, Perugia
202	OC 63	Predicted HIV-1 tropism on plasma and cerebrospinal fluid is associated with neurocognitive disorders	Ilaria Motta, Torino
340	OC 64	Dolutegravir trough concentration and neuropsychiatric symptoms in a cohort of HIV-infected patients on stable antiretroviral therapy	Alberto Borghetti, Roma
96	OC 65	HIV, complications and comorbidities: economic evidence from the field	Elisabetta Garagiola, Castellanza VA
282	OC 66	Hyperbilirubinemia is associated with a decreased risk of carotid atherosclerosis in HIV-infected patients with virological suppression	Camilla Muccini, Milano
258	OC 67	How many and which HIV patients with fatty liver are at risk of progressive liver disease?	Marianna Menozzi, Modena
14/06/2017 10.35 - 11.55 HIV: Walking along the continuum of care			
<i>Aula 2 Chairs: M. Farinella, M. Oldrini, F. von Schloesser</i>			
76	OC 68	Anlaidis Lazio inside chat lines: prevention and counseling through mobile apps	Rosario Galipo, Roma
120	OC 69	HIV self-testing in Italy	Nicoletta Orchi, Roma
140	OC 70	Testing MSM in cruising venues	Donatello Zagato, Milano
87	OC 71	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for HIV-infected people	Annalisa Saracino, Bari
316	OC 72	Perceptions of barriers for optimal Retention in Care in people with HIV: a national survey	Pierluca Piselli, Roma
18	OC 73	Social media and people with HIV: work in progress. Results from an Italian survey	Arianna Donti, Modena
145	OC 74	Causes of switch of antiretroviral treatment in a cohort of HIV+ subjects. Analysis of ten years registered trends (2007-2016)	Benedetto Maurizio Celesia, Catania
14/06/2017 14.00 - 15.30 Hepatitis: epidemiology and basic research			
<i>Aula 1 Chairs: A. Calcagno, S. Di Giambenetto, M. Lichtner</i>			
346	OC 75	An outbreak of acute hepatitis A among young adult men in Rome: the experience of a large teaching hospital	Arturo Ciccullo, Roma
273	OC 76	Huge decrease of hepatocellular apoptosis in both HIV/HCV co-infected and HCV mono-infected patients undergoing IFN free therapy despite persistence of inflammation	Paola Zuccalà, Roma
293	OC 77	HCV genotype 3 resistance profile characterization in DAA-naïve and DAA-failed patients in Italy	Silvia Barbaliscia, Roma
254	OC 78	Complex and frequent multiclass HCV resistance in almost all HCV genotypes at DAA failure: what chances for second-line regimens?	Velia Chiara Di Maio, Roma
114	OC 79	Positively charged mutations in HBsAg C-terminus are tightly correlated with HBV-induced hepatocellular carcinoma and profoundly hamper the structural folding of this domain	Romina Salpini, Roma
115	OC 80	An extensive degree of genetic variability characterizes Hepatitis Delta Antigen and correlates with elevated serum HDV-RNA levels	Luna Colagrossi, Roma
195	OC 81	Irreversible Circulating Mucosal associated invariant T cells (MAITs) loss despite successful interferon-free therapy in chronically HIV/HCV co-infected patients	Elvira Stefania Cannizzo, Milano
127	OC 82	HCV-genotype 3h: is a difficult-to-diagnose and to-treat HCV sub-genotype in the DAA' era?	Carmine Minichini, Napoli
44	OC 83	Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV-HCV co-infected individuals	Davide Fiore Bavaro, Bari



Elenco Oral Communication Oral Communications

ID	N. pgm	Title	Presenting Author
14/06/2017 14.00 - 15.30 Basic Science and clinical virology			
<i>Aula 2 Chairs: M. Clementi, M.C. Re, S. Rusconi</i>			
213	OC 84	HIV-1 B subtype underwent a deep genetic evolution that impacted its pathogenic potential over the years 2003-2016	Claudia Alteri, Roma
78	OC 85	Very low level residual viremia do correlate with HIV-DNA load in successfully suppressed individuals on cART	Annapaola Callegaro, Bergamo
224	OC 86	HIV-1 tropism evolution is reduced in presence of Integrase Inhibitors based regimens	Rossana Scutari, Roma
90	OC 87	HIV-1 non-R5 tropism correlates with higher residual viral replication and a larger size of the cellular viral reservoir in patients under suppressive ART	Francesca Lombardi, Roma
105	OC 88	Long-term Impact of Monotherapy on HIV-1 Reservoir, Immune Activation and Epstein-Barr Virus Co-infection	Maria Raffaella Petrara, Padova
214	OC 89	Variability of sumoylation sites in HIV-1 integrase correlates with viro-immunological parameters and integrase resistance	Daniele Armenia, Roma
235	OC 90	HIV transmitted drug resistance in patients recently diagnosed with HIV from 2011 to 2016 in ASST GOM Niguarda	Pamela Tau, Milano
409	OC 91	Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI)	Chiara Spertilli Raffaelli, Siena
81	OC 92	Prevalence of resistance mutations to Integrase Inhibitors in INSTI-experienced HIV-1 infected patients in a large Italian cohort	Sara Modica, Siena